탄산란탄

용도

• Phosphate binder
• Phosphate binder (using Renalzin)
• Chronic kidney disease (Hyperphosphataemia)
• Chronic kidney disease (Hyperphosphataemia)

투여 방법

가능한 부작용

• Vomiting
• Nausea
• Inappetence
• None known according to the monograph
• Gastrointestinal upset (nausea, vomiting, diarrhea, or constipation) may occur (Clinical Pearl)

주의사항 및 금기

• Patients with non-intact GI tract (e.g., GI ulcers, colitis) - use with caution due to increased risk of systemic absorption
• Acute renal crisis (patients should be stabilized first)
• There are no listed absolute contraindications, but it should be used with caution in patients where the GI tract is not intact (e.g., GI ulcers, colitis) as there is an increased chance for oral absorption. Safe for use during pregnancy and nursing.

약물 상호작용

• Allopurinol: Potential decreased absorption; separate dosing by 2 hours
• Chloroquine: Potential decreased absorption; separate dosing by 2 hours
• Corticosteroids: Potential decreased absorption; separate dosing by 2 hours
• Digoxin: Potential decreased absorption; separate dosing by 2 hours
• Ethambutol: Potential decreased absorption; separate dosing by 2 hours
• Fluoroquinolones: Potential decreased absorption; separate dosing by 2 hours
• H-2 Antagonists (ranitidine, famotidine): Potential decreased absorption; separate dosing by 2 hours
• Iron Salts: Potential decreased absorption; separate dosing by 2 hours
• Isoniazid: Potential decreased absorption; separate dosing by 2 hours
• Penicillamine: Potential decreased absorption; separate dosing by 2 hours
• Phenothiazines: Potential decreased absorption; separate dosing by 2 hours

자주 묻는 질문